Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

To: stockdoc77 who wrote (50164)	2/8/2019 1:33:52 PM
From: allatwwk	6 Recommendations of 63284

Of all the things posted since the CRL, the most disconcerting was the 38/38 track record by the FDA on accelerated approvals (I didn't have this info, but it was posted by a reliable poster, so I'll assume they got it correct). Now its 38-1 and IMMU is the 1. I'm not sure what to make of it, but it isn't good. There is a disconnect between FDA and IMMU and I have no idea what it really is or what is behind it. A lot of things don't really add up at this point, but I am certain of one thing: IMMU is now an execution story and mgmt has got to execute. Until they get an approval, I don't see anything (other than a buyout) which will move the shares a lot. They have to show they can get a product approved. At this point, I only care a little bit about what mgmt says. I'd appreciate clarity, but I don't really need it. It isn't about words anymore.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next